Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP1 in Primary Melanoma
NCT06216938Phase 1Recruiting
- Start
- Mar 2024
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vusolimogene oderparepvec in melanoma. Primary endpoint: Rate of Sentinel Lymph Node Positivity at 2 years. Started Mar 2024; status: recruiting.
02
Drugs
vusolimogene oderparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06216938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216938.